HIF-1 is involved in the negative regulation of AURKA expression in breast cancer cell lines under hypoxic conditions

AbstractNumerous microarray-based gene expression studies performed on several types of solid tumors revealed significant changes in key genes involved in progression and regulation of the cell cycle, including AURKA that is known to be overexpressed in many types of human malignancies. Tumor hypoxia is associated with poor prognosis in several cancer types, including breast cancer (BC). Since hypoxia is a condition that influences the expression of many genes involved in tumorigenesis, proliferation, and cell cycle regulation, we performed a microarray-based gene expression analysis in order to identify differentially expressed genes in BC cell lines exposed to hypoxia. This analysis showed that hypoxia induces a down-regulation of AURKA expression. Although hypoxia is a tumor feature, the molecular mechanisms that regulate AURKA expression in response to hypoxia in BC are still unknown. For the first time, we demonstrated that HIF-1 activation downstream of hypoxia could drive AURKA down-regulation in BC cells. In fact, we found that siRNA-mediated knockdown of HIF-1α significantly reduces the AURKA down-regulation in BC cells under hypoxia. The aim of our study was to obtain new insights into AURKA transcriptional regulation in hypoxic conditions. Luciferase reporter assays showed a reduction of AURKA promoter activity in hypoxia. Unlike the previous findings, we hypothesize a new possible mechanism where HIF-1, rather than inducing transcriptional activation, could promote the AURKA down-regulation via its binding to hypoxia-responsive elements into the proximal region of the AURKA promoter. The present study shows that hypoxia directly links HIF-1 with AURKA expression, suggesting a possible pathophysiological role of this new pathway in BC and confirming HIF-1 as an important player linking an environmental signal to the AURKA promoter. Since AURKA down-regulation overrides the estrogen-mediated growth and chemoresistance in BC cells, these findings could be important for the development of new possible therapies against BC.

[1]  P. V. van Diest,et al.  HIF-1α Overexpression in Ductal Carcinoma In Situ of the Breast in BRCA1 and BRCA2 Mutation Carriers , 2013, PloS one.

[2]  Gordon K. Smyth,et al.  affylmGUI: a graphical user interface for linear modeling of single channel microarray data , 2006, Bioinform..

[3]  H. Iwase,et al.  Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer , 2008, Breast Cancer Research and Treatment.

[4]  K. Stoeber,et al.  The cell cycle and cancer , 2012, The Journal of pathology.

[5]  V. Adamo,et al.  The role of Aurora-A inhibitors in cancer therapy. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Stephen L. Brown,et al.  Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas , 2012, Cell cycle.

[7]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[8]  R. Lech,et al.  Epidemiological models for breast cancer risk estimation. , 2011, Ginekologia polska.

[9]  H. Mori,et al.  Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. , 1999, Cancer research.

[10]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[11]  A. Harris,et al.  Tumour hypoxia, hypoxia signaling pathways and hypoxia inducible factor expression in human cancer. , 2001, Anticancer research.

[12]  Adrian L Harris,et al.  Hypoxia and oxidative stress in breast cancer: Hypoxia and tumourigenesis , 2001, Breast Cancer Research.

[13]  M. Pagano,et al.  Constitutive Phosphorylation of Aurora-A on Ser51 Induces Its Stabilization and Consequent Overexpression in Cancer , 2007, PloS one.

[14]  Peter Vaupel,et al.  The role of hypoxia-induced factors in tumor progression. , 2004, The oncologist.

[15]  G. Gopalan,et al.  Downregulation of Aurora-A overrides estrogen-mediated growth and chemoresistance in breast cancer cells. , 2007, Endocrine-related cancer.

[16]  Choa Park,et al.  Hypoxia-inducible factor 1 alpha represses the transcription of the estrogen receptor alpha gene in human breast cancer cells. , 2011, Biochemical and biophysical research communications.

[17]  J. Bussink,et al.  Molecular aspects of tumour hypoxia , 2008, Molecular oncology.

[18]  D. Fisher,et al.  Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF , 2011, Proceedings of the National Academy of Sciences.

[19]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[20]  J Martin Brown,et al.  Tumor Microenvironment and the Response to Anticancer Therapy , 2002, Cancer biology & therapy.

[21]  J. Simons,et al.  Hypoxia-inducible factor-1 in human breast and prostate cancer. , 2006, Endocrine-related cancer.

[22]  J. Ingels,et al.  Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer , 2012, Breast Cancer Research.

[23]  Qing Jiang,et al.  Roles of Aurora Kinases in Mitosis and Tumorigenesis , 2007, Molecular Cancer Research.

[24]  Ko-Fan Chen,et al.  Transcriptional repression of human cad gene by hypoxia inducible factor-1α , 2005, Nucleic acids research.

[25]  F. Gergely,et al.  Aurora-A: the maker and breaker of spindle poles , 2007, Journal of Cell Science.

[26]  G. Semenza,et al.  Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. , 2005, Blood.

[27]  A. Dunker,et al.  Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data , 2008, BMC Medical Genomics.

[28]  W. Kaelin,et al.  The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. , 2003, Journal of the American Society of Nephrology : JASN.

[29]  R. Medema,et al.  Shared and separate functions of polo-like kinases and aurora kinases in cancer , 2010, Nature Reviews Cancer.

[30]  G. Semenza Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.

[31]  C. Pugh,et al.  Hypoxia and oxidative stress in breast cancer: Hypoxia signalling pathways , 2001, Breast Cancer Research.

[32]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[33]  Ahmedin Jemal,et al.  Breast cancer statistics, 2011 , 2011, CA: a cancer journal for clinicians.

[34]  T. Kietzmann,et al.  Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1. , 2008, Molecular biology of the cell.

[35]  S. Lens,et al.  The Aurora kinase family in cell division and cancer. , 2008, Biochimica et biophysica acta.

[36]  A. Jukkola-Vuorinen,et al.  Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients , 2012, Breast Cancer Research and Treatment.

[37]  Benjamin M. Bolstad,et al.  affy - analysis of Affymetrix GeneChip data at the probe level , 2004, Bioinform..

[38]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[39]  Huan Yang,et al.  Aurora‐A induces cell survival and chemoresistance by activation of Akt through a p53‐dependent manner in ovarian cancer cells , 2006, International journal of cancer.

[40]  A. Sood,et al.  p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation , 2012, Cell cycle.

[41]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Hiroshi Katayama,et al.  The Aurora kinases: Role in cell transformation and tumorigenesis , 2003, Cancer and Metastasis Reviews.

[43]  A. Jemal,et al.  Breast Cancer Statistics , 2013 .

[44]  C. Golias,et al.  Cell proliferation and cell cycle control: a mini review , 2004, International journal of clinical practice.

[45]  P. Maxwell,et al.  VHL inactivation induces HEF1 and Aurora kinase A. , 2010, Journal of the American Society of Nephrology : JASN.

[46]  Feng Jiang,et al.  Amplification/overexpression of a mitotic kinase gene in human bladder cancer. , 2002, Journal of the National Cancer Institute.

[47]  Hagen Schmal,et al.  Development and Characterization of a Spheroidal Coculture Model of Endothelial Cells and Fibroblasts for Improving Angiogenesis in Tissue Engineering , 2005, Cells Tissues Organs.

[48]  A. Giordano,et al.  R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair , 2010, Molecular Cancer.

[49]  Melissa L. Johnson,et al.  Emerging targeted therapies for breast cancer. , 2007, Hematology/oncology clinics of North America.

[50]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[51]  Manfred Kunz,et al.  Molecular responses to hypoxia in tumor cells , 2003, Molecular Cancer.

[52]  D. Xing,et al.  The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. , 2010, Cancer research.

[53]  Simon Lord,et al.  Gene expression and hypoxia in breast cancer , 2011, Genome Medicine.

[54]  H. Frierson,et al.  Expression profiling of gastric adenocarcinoma using cDNA array , 2001, International journal of cancer.